We focused on PDE3A-regulated nanodomains, anticipating that knowledge of where these domains are located may help identify pathways involved in the long-term adverse cardiac effects observed in patients with HF receiving PDE3 inhibitors. This evidence concerns the gene PDE3A and hydrops fetalis.